Brodalumab is a human monoclonal antibody designed for the treatment of inflammatory diseases. It is being tested for the treatment of moderate to severe psoriasis in Phase III clinical trials as of November 2013.Brodalumab was developed by Amgen Inc.
This page contains content from the copyrighted Wikipedia article "Brodalumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.